Kate Owen

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia

Hagop M. Kantarjian, Giovanni Martinelli, Elias Jabbour et al. · Cancer · 2013 · 105 citations · Full text

Medicine, Hematology, Pharmacology +14

Programmed Death Ligand 1 (<i>PD</i>-<i>L1</i>) Gene Variants Contribute to Autoimmune Addison’s Disease and Graves’ Disease Susceptibility

Anna L. Mitchell, Heather J. Cordell, Rachel Soemedi et al. · The Journal of Clinical Endocrinology & Metabolism · 2009 · 75 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

Hagop M. Kantarjian, Mikkael A. Sekeres, Vincent Ribrag et al. · Clinical Lymphoma Myeloma & Leukemia · 2013 · 58 citations

Medicine, Pharmacology, Pharmacotherapy +3

Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, Mikkael A. Sekeres, Vincent Ribrag et al. · Blood · 2010 · 15 citations

Medicine, Oncology, Pharmacology +13

Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse.

Kate Owen, Toshio Shibata, Shozo Izui et al. · PubMed · 1989 · 10 citations

Life Sciences, Immunology, Pathology +15